Search the Newsreel

Superhouse reports consolidated net profit of Rs 3.56 crore in the June 2026 quarter

Superhouse Q1 Results: Standalone profit turns positive at ₹556 lakh

Superhouse Board to Approve Q4FY26 Results on August 13

Superhouse Ltd Nine Monthly Results, Nine Monthly Earnings for Superhouse Ltd

ChemoMetec enters collaboration agreement with Roche Diagnostics

Chemometec A/S ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties' solutions in the field of bioprocess monitoring, ChemoMetec and Roche Diagnostics have today …

Roche Stock Jumps as Morgan Stanley Sees Drug Breakout

This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. …

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

Net cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months of 2026; quarter-end cash and restricted cash position was $289.1 million Guidance …

Powerhouse Ventures (ASX:PVL) Dips as Financials Sector Faces Headwinds

RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down

Recursion Pharmaceuticals RXRX reported a loss of 25 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 23 cents. The company had incurred a loss of 41 cents per share in the year-ago quarter. …

Roche expands cyclospora testing portfolio to support U.S. public health response

Roche has launched two new, real-time PCR tests to detect cyclospora, a diarrhea-causing infection, to help meet diverse needs of laboratories. The new tests expand the Roche cyclospora portfolio, providing laboratories with more flexible choices. Cyclospora tests are another example of Roche's leadership in …

Nurix Therapeutics (NRIX) Lands $10 Million Milestone As Phase 3 Trial Begins

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Nurix Therapeutics (NasdaqGM:NRIX) announced a $10 million milestone payment tied to the first in human trial of an oral STAT6 degrader in its …

The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership

IDEAYA Biosciences recently reported a second-quarter 2026 net loss of US$112.45 million, or US$1.22 per basic and diluted share, while also disclosing a wider six‑month loss versus the prior year. In parallel, IDEAYA advanced its precision oncology pipeline by initiating Part 2 monotherapy expansion …

Powerhouse Ventures (ASX:PVL) Why AI’s Next Bottleneck Could Be Gas, Not Chips

Powerhouse Energy Group Stock Price Forecast. Should You Buy PHE.L?

Superhouse Share Price Forecast to 2030

Powerhouse Ventures Posts Record Revenue as Advisory and Funds Arms Scale Up

Roche (SWX:ROP) Wins FDA Clearance And EU Backing For Two Key Treatments

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Roche Holding (SWX:ROP) received FDA clearance for its cobas BV/CV assay for diagnosing bacterial vaginosis and Candida vaginitis in the United States. The European Medicines Agency's Committee …

Times Neighborhood Holdings Ltd. Revenue Breakdown – HKEX:9928

[Latest] Global Precision Diagnostics And Medicine Market Size/Share Worth USD 345.75 Billion by 2035 at a 8.91% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Precision Diagnostics And Medicine Market size & share revenue was valued at approximately USD 147.23 Billion in 2025 and is expected …

Newleos Names Rohan Palekar as Board Chairman

– Prominent biotech leader and former Chief Executive Officer of 89bio joins Newleos Board of Directors – BOSTON, July 28, 2026--(BUSINESS WIRE)--Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced the appointment of Rohan Palekar to its Board …

Powerhouse Ventures (ASX:PVL) Advances 7.69% and Extends Its Annual Gain

How Roche Unexpectedly Buoyed IBD Stock Of The Day TG Therapeutics

TG Therapeutics is Friday's IBD Stock Of The Day after shares rebounded into a profit-taking zone on key comments from chief rival Roche. Continue Reading

Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis

The new PCR test uses clinician-collected or clinician-instructed, self-collected vaginal swab specimens to simultaneously detect organisms associated withBacterial vaginosis(BV) andCandida vaginitis(CV). This molecular assay can help improve diagnostic accuracy for symptomatic women affected by vaginitis, compared to traditional methods.¹ The assay expands the sexual-health …

CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)

F. Hoffmann-La Roche Ltd Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye injections for nAMD Positive recommendation is based on data from the LADDER, Archway and Portal studies showing Susvimo maintained vision equivalent to …

Roche Cuts Generic Sales Hit to $736 Million, Shares Jump 3.2%

This article first appeared on GuruFocus. Roche Holding AG (RHHBF), a Swiss drugmaker, has reduced the amount of revenue it expects to lose to cheaper generic competition this year, offering investors a more favorable near-term outlook. The company now expects copycat medicines to reduce …

Roche Holding AG (RHHBF) (Half Year 2026) Earnings Call Highlights: Strong Financial ...

This article first appeared on GuruFocus. Release Date: July 23, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Roche Holding AG (RHHBF) reported a strong financial performance with a 10% increase in co-operating …

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc

F. Hoffmann-La Roche Ltd Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2, in the first six months, driven by high demand for innovative medicines and diagnostics. Pharmaceuticals Division sales were +6% at CER, -1% …

Roche (SWX:ROP) Appoints Dan Malarek To Lead Its North America Diagnostics Business

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Roche Holding (SWX:ROP) has appointed Dan Malarek as President and CEO of Roche Diagnostics …

Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026 to help laboratories address workforce and workflow challenges

Supporting ADLM's focus on collaborative, cross-disciplinary solutions that address laboratory workforce and operational challenges Highlighting innovations in mass spectrometry, next-generation sequencing, digital pathology and AI diagnostics Showcasing Roche's portfolio across core, molecular and pathology labs and point-of-care settings at booth no. 2901 INDIANAPOLIS, July …

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Nurix Therapeutics, Inc. BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the closing of its previously announced global collaboration agreement with …

Unlock Trust and ROI: Graphwise Announces Free Virtual Summit to Help Leaders Secure Real Value from Enterprise AI

Bringing together experts from organizations like Accenture, Roche, and S&P Global on October 7–8, this virtual summit delivers a proven blueprint for building explainable, scalable AI systems that deliver measurable business impact. NEW YORK, July 21, 2026 /PRNewswire/ -- CIOs and business leaders face …

Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America

Dan Malarek, current CEO of Foundation Medicine Inc., appointed President and CEO of Roche Diagnostics North America, effective August 1, 2026 Malarek succeeds Brad Moore, who will retire at the end of July following nearly a decade of distinguished service at Roche Antonio Vergara …

Enterprise value to revenue forward of Powerhouse Energy Group PLC – LSE:PHE